Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Automationguyon Mar 26, 2012 7:38am
348 Views
Post# 19716725

RE: RE: if we get good nr next week, now thats a b

RE: RE: if we get good nr next week, now thats a b

I wish the news will not be like Canacol this morning !

Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE) (BVC:CNEC) provides the following update on the recompletion of the Agueda 1 well on its LLA 23 Exploration and Production ("E&P") Contract (80% operated working interest) located in the Llanos Basin of Colombia. The Agueda 1 well was successfully re-entered and tested formation water from two sandstone reservoirs in the C7 reservoir.

The Agueda 1 well was drilled in 2007 and bypassed oil pay was identified by the Corporation within the C7 reservoir. Two of the three C7 sandstone reservoirs were perforated between 8,803-17 and 8,886-8,904 ft md and tested in the well, with each zone producing formation water at high rates. The well has been suspended as a potential future water injection well should the Corporation realize exploration success in any of the exploration prospects the Corporation plans to drill on the LLA 23 E&P contract later in 2012

Bullboard Posts